Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TARRYTOWN, N.Y., Nov. 9, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced third quarter 2011 results of operations. "We have been pleased by the efforts of our...
-
TARRYTOWN, N.Y., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at two upcoming investor conferences in New York City: Brean...
-
TARRYTOWN, N.Y., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) will host a conference call and webcast to discuss its financial results for the third quarter of 2011...
-
TARRYTOWN, N.Y., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at the 18th Annual "NewsMakers in the Biotech Industry" conference...
-
TARRYTOWN, N.Y., Sept. 16, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that Chief Executive Officer Mark R. Baker will present at the UBS Global Life...
-
— Highlights actions resulting from strategic review — — Conference call and webcast today at 8:30 a.m. ET — TARRYTOWN, N.Y., Sept. 15, 2011 (GLOBE NEWSWIRE) --...
-
— Second quarter U.S. sales of RELISTOR® increased 99% over first quarter and 50% over prior year quarter — — Enrollment in phase 3 trial of oral methylnaltrexone completed...
-
TARRYTOWN, N.Y., June 28, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...
-
TARRYTOWN, N.Y., June 2, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that Mark Baker, the Company's chief executive officer, will present a company update at...
-
TARRYTOWN, N.Y., May 20, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today provided analyses of safety and efficacy endpoints from the 1,034-patient, one-year phase 3 safety...